Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nnc9204-1513
- Development stage
- Phase 1
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
NNC9204-1513 (also known as NN9513 or HypoPen 1513) is a subcutaneously administered glucagon receptor agonist developed by Novo Nordisk for the rescue treatment of severe hypoglycemia. It is designed as an easy-to-use injectable product for emergency management of low blood sugar episodes. The drug acts by stimulating the glucagon receptor to rapidly increase blood glucose levels through hepatic glycogenolysis and gluconeogenesis. As of the latest available information, NNC9204-1513 has completed phase I clinical trials but has not advanced further in development or reached the market[1][2][3].
- Brand names
- HypoPen 1513HypoPen1513HypoPen-1513
- Other names
- NNC9204 1513NNC-9204 1513NNC 9204 1513NN9513NN-9513NN 9513
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on nnc9204-1513.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nnc9204-1513.